Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.
Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Imran Omar M, Alshammari T, Areia C, Asiimwe A, Beyer K, Bjartell A, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai LYH, Maresca G, Mottet N, Oja M, Prinsen P, Reich C, Remmers S, Roobol MJ, Sakalis V, Seager S, Smith EJ, Snijder R, Steinbeisser C, Thurin NH, Hijazy A, van Bochove K, Van den Bergh RCN, Van Hemelrijck M, Willemse PP, Williams AE, Zounemat Kermani N, Evans-Axelsson S, Briganti A, N'Dow J; PIONEER Consortium. Gandaglia G, et al. Among authors: van bochove k. Eur Urol. 2024 May;85(5):457-465. doi: 10.1016/j.eururo.2023.06.012. Epub 2023 Jul 5. Eur Urol. 2024. PMID: 37414703 Free article.
Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, Briganti A, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ, Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, N'Dow J; PIONEER Consortium. Omar MI, et al. Among authors: van hemelrijck m, van bochove k, van diggelen f, van poppel h. Nat Rev Urol. 2020 Jun;17(6):351-362. doi: 10.1038/s41585-020-0324-x. Epub 2020 May 27. Nat Rev Urol. 2020. PMID: 32461687 Review.
The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer.
Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briers E, Omar MI, Healey J, Tripathee S, Gandaglia G, Venderbos LDF, Smith EJ, Bjorkqvist J, Asiimwe A, Huber J, Roobol MJ, Zong J, Bjartell A, N'Dow J, Briganti A, MacLennan S, Van Hemelrijck M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECPC; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF-eCancer; AstraZeneca; HelmHoltz. Beyer K, et al. Eur Urol Focus. 2021 Sep;7(5):943-946. doi: 10.1016/j.euf.2021.09.008. Epub 2021 Oct 1. Eur Urol Focus. 2021. PMID: 34602368 Free article.
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J; PIONEER Consortium. Omar MI, et al. Nat Rev Urol. 2023 Aug;20(8):494-501. doi: 10.1038/s41585-023-00748-9. Epub 2023 Apr 3. Nat Rev Urol. 2023. PMID: 37012441 Review.
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, Briganti A, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ, Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, N'Dow J; PIONEER Consortium. Omar MI, et al. Among authors: van hemelrijck m, van bochove k, van diggelen f, van poppel h. Nat Rev Urol. 2020 Aug;17(8):482. doi: 10.1038/s41585-020-0355-3. Nat Rev Urol. 2020. PMID: 32587405
Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol.
Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, Maclennan SJ, Devecseri Z, Asiimwe A, Collette L, Bjartell A, Ndow J, Briganti A, Van Hemelrijck M; PIONEER Consortium. Beyer K, et al. BMJ Open. 2021 Feb 11;11(2):e040531. doi: 10.1136/bmjopen-2020-040531. BMJ Open. 2021. PMID: 33574142 Free PMC article.
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Van Hemelrijck M, et al. Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29. Eur Urol. 2019. PMID: 30385049 Free PMC article.
Using the Movember Foundation's GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function-a retrospective study in low-risk prostate cancer patients.
Crump RT, Remmers S, Van Hemelrijck M, Helleman J, Nieboer D, Roobol MJ, Venderbos LDF; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Crump RT, et al. Transl Androl Urol. 2021 Jun;10(6):2719-2727. doi: 10.21037/tau-20-1255. Transl Androl Urol. 2021. PMID: 34295757 Free PMC article.
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.
Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium. Olivier J, et al. Eur Urol Open Sci. 2022 Jan 3;35:59-67. doi: 10.1016/j.euros.2021.11.006. eCollection 2022 Jan. Eur Urol Open Sci. 2022. PMID: 35024633 Free PMC article.
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Remmers S, et al. Eur Urol Open Sci. 2022 Jun 14;41:126-133. doi: 10.1016/j.euros.2022.05.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813247 Free PMC article.
36 results